US FDA First-Cycle ANDA Approvals Not Rising Along With Full Clearances

While FDA is on pace to again break its record for full ANDA approvals in FY 2019, the first-cycle approval rate is dropping, as illustrated in our charts.

FDA approved background, 3D rendering, blue street sign
Why are first-cycle approvals not increasing when overall ANDA approvals are on pace for another annual record? • Source: Shutterstock

The US Food and Drug Administration continues issuing a consistent number of first-cycle ANDA approvals each month, and in a cruel twist of statistics, that means its performance is suffering.

Through April, the FDA issued 625 full ANDA approvals in FY 2019, a substantial increase from the same period in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

Generic Drug Industry Seeks More US FDA Communication Reforms In GDUFA Renewal

 
• By 

Enhancing the consistency and clarity of information requests and discipline review letters, and improving assessment milestone communications are key areas targeted by generic drug makers for user fee program negotiations.

Aurobindo Expects US FTC Will Allow Lannett Acquisition

 
• By 

Aurobindo is confident its planned Lannett acquisition will meet US FTC standards after an attempt to acquire Sandoz assets was nixed in 2020. The deal also could widen Aurobindo’s US manufacturing presence.

US FDA Skips User Fee Increase For More Staff Amid Exodus, Hiring Difficulties

 
• By 

A calculation used to determine whether the FDA has the staff to handle its workload also was not included in the description of prescription drug user fee calculations.

Court Allows MSN Marketing Of Entresto Generic, But More Legal Issues Pending

 
• By 

Novartis failed to stop MSN from launching a generic Entresto and saw an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.

More from Biosimilars & Generics

EU Biosimilar Filings, Opinions And Approvals

 
• By 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Court Allows MSN Marketing Of Entresto Generic, But More Legal Issues Pending

 
• By 

Novartis failed to stop MSN from launching a generic Entresto and saw an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.

Generic Drugs And AI: Maximum Daily Dose Tool Could Help US FDA Be ‘At The Forefront’

 
• By 

The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.